(Total Views: 317)
Posted On: 12/16/2018 7:10:56 PM
Post# of 72436
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
The swamp is busy this weekend trying there level best to tamp down FDA expectations going into EOP2. What we do know is B for OM has shown statistically significant therapeutic benefit by decreasing the incidence of SOM. B oral rinse has low systemic absorption, FDA should love this aspect imo. We are going against a hugely unmet debilitating disease so for crying out loud why wouldn't FDA get excited about it as well as our licensing partner.
http://www.ipharminc.com/press-release/2018/9...treatments
http://www.ipharminc.com/press-release/2018/9...treatments
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)